

1

2

---

**Continuous pain report demonstrates time delay of pain ratings in**

3

**Fibromyalgia**

---

4

5

Anna Y Kharko <sup>1</sup>, Stephen D Hall <sup>1</sup>, Paul L Furlong <sup>2</sup>, Matthew E Roser <sup>1</sup>

6

7

<sup>1</sup> Brain Research & Imaging Centre, Faculty of Health, University of Plymouth

8

<sup>2</sup> Aston Brain Centre, Faculty of Life & Health Sciences, Aston University

9

10 **Corresponding author**

11 Anna Yurievna Kharko, Faculty of Health, 208 Link Building, University of Plymouth,  
12 Drake Circus, Plymouth PL4 8AA, UK.

13 Email: [anna.kharko@plymouth.ac.uk](mailto:anna.kharko@plymouth.ac.uk)

14

## ABSTRACT

15 **Background:** Enhanced temporal summation (TS), measured through self-reported  
16 pain ratings, has been interpreted as indicative of central sensitisation in  
17 fibromyalgia. Greater TS in patients, however, has not been universally observed. It  
18 is also unclear whether increased pain report maintains beyond the TS period.

19 **Methods:** In this study, we measured TS through continuously reported pain ratings.  
20 Fibromyalgia-diagnosed patients ( $n = 17$ ) and matched pain-free controls ( $n = 13$ )  
21 rated painful transcutaneous electrical stimulation of various intensity levels in 18  
22 one-minute-long blocks. Pain was rated on a 101-point visual analogue scale. The  
23 resulting continuous response was divided into TS ( $< 15s$ ) and adaptation ( $15 - 60s$ )  
24 periods. Average pain values were extracted for each period alongside the timing of  
25 key events such as maximal pain ratings. The difference in temporal summation and  
26 adaptation measures between fibromyalgia and control participants was analysed  
27 using mixed-effects modelling.

28 **Results:** The average pain ratings for TS and adaptation periods were not  
29 significantly associated with fibromyalgia diagnosis but were with stimulation  
30 intensity. The same was true for the magnitude of the maximal rating during TS and  
31 the slope leading to that peak rating. The presence of fibromyalgia, however, did  
32 predict the time of the maximal TS rating, as well as the value and the time of the  
33 maximal adaptation rating.

34 **Conclusions:** Our study did not find homogeneously increased TS pain ratings.  
35 Instead, by utilising continuous pain data we demonstrate for the first time that the  
36 time of TS peak rating, as well as the magnitude and time of adaptation peak rating  
37 are linked to fibromyalgia diagnosis.

38

### 39 **Keywords**

40 fibromyalgia, temporal summation, continuous pain ratings, transcutaneous electrical  
41 stimulation, pain, experimental pain, chronic pain

## 42 INTRODUCTION

43 Fibromyalgia (FM) is a chronic widespread pain condition of unknown aetiology,  
44 associated with disrupted sleep, fatigue and mild cognitive disturbances; resulting in  
45 high emotional burden (Clauw, 2014). The high prevalence, 2% to 5% of the  
46 population (Queiroz, 2013), and limited long-term success of symptom management  
47 (Häuser et al., 2014), has put pressure on understanding the mechanisms that  
48 underlie pain processing in FM. Allodynia and hyperalgesia, the key markers of FM  
49 pain (Sluka & Clauw, 2016), have been attributed to deficient pain inhibition in the  
50 central nervous system (CNS) (Meeus & Nijs, 2007), a phenomenon known as  
51 central sensitisation. In psychophysical research, it has been studied through  
52 temporal summation (TS).

53 TS is the increase in reported pain in response to unremitting stimulation at a  
54 fixed frequency (Arendt-Nielsen et al., 2000). It is considered the behavioural  
55 counterpart of wind-up (WU), a central spinal mechanism where an increased  
56 excitation of dorsal horn neurons is observed following repeated engagement of C-  
57 fibres (Gebhart & Schmidt, 2013). While TS and WU are part of healthy nociception,  
58 both have been reported to be augmented in chronic pain conditions, such as FM  
59 (Staud, 2012).

60 The majority of observations on TS in FM come from a series of studies began  
61 by Staud and Price (Staud et al., 2001). They have reported that FM patients require  
62 lesser stimulation intensity than pain-free controls to produce similar TS pain ratings  
63 (Staud et al., 2003). Further, maintenance of TS required less stimulation in the FM  
64 cohort than control (Staud et al., 2004). Importantly, this pattern of increased TS in  
65 FM has been demonstrated across several stimulation modalities (Graven-Nielsen et  
66 al., 2000; Staud et al., 2003, 2014).

67 Greater TS in FM, however, is not a universally-observed phenomenon.  
68 Several studies report mixed results, in which increased TS in patients was  
69 contingent on stimulation location or modality (for review see O'Brien (2018). One  
70 study failed to find any deviancy in the clinical cohort (Lim et al., 2016). Part of this  
71 literature heterogeneity may stem from varying methods of TS elicitation and  
72 measurement. The conventional approach dictates deriving a measure based on  
73 comparison between a single pain rating and a later rating following repeated

74 stimulation at a frequency that evokes TS (Lim et al., 2016; Staud et al., 2001). Such  
75 a low rate of pain sampling provides a coarse measure of the *temporal* aspect of TS  
76 and does not show whether the enhanced pain perception maintains beyond the  
77 period of TS. The following period, here termed adaptation, is also a marker of WU  
78 and can be used to characterise central sensitisation (Graven-Nielsen et al., 2000)  
79 but has not yet been adopted in FM.

80 The conventional approach has limited utility. Firstly, the use of singular pain  
81 ratings does not capture the possible development of pain perception across a fixed  
82 interval. Secondly, the reporting of a single value from a point in time is likely subject  
83 to high measurement error and individual variation. Thirdly, the serial processes of  
84 summation and adaptation are likely to be conflated by use of a fixed measurement  
85 point and the temporal envelope of these processes overlooked.

86 Here, we describe the collection of continuous pain ratings, to address the  
87 limitations of single fixed pain reports. Continuous pain ratings, concurrent to  
88 stimulation, have been found to reliably reflect acute pain perception (Boormans et  
89 al., 2009; Wijk et al., 2013). In FM research, one study used continuous pain report  
90 but did not analyse the time property of the gathered pain data (Potvin et al., 2012).  
91 The extraction of key timepoints from TS and adaptation for comprehensive analysis  
92 of acute pain processing in the presence of FM is yet to be done.

93 To address this, we carried out a study with FM patients and pain-free controls  
94 using transcutaneous electrical stimulation (TES), a well-established method for  
95 eliciting TS (Arendt-Nielsen et al., 2000). We applied tonic single-pulse TES at  
96 individual-derived intensity levels and asked participants to rate their pain  
97 continuously on an automated visual analogue scale (VAS). We anticipated that  
98 time, a new property of the extracted data, will be the key measure to characterise  
99 TS in FM.

100

## 101 **METHODS**

### 102 **2.1. Participants**

103 Participants were recruited on the basis of several strict eligibility criteria (see  
104 Table 1). Ethical permission was granted by the School of Psychology, University of  
105 Plymouth (17/18-890).

106

107 *Table 1.* Eligibility Requirements for Participation

<b>All Participants</b>	
(a) Age	18 to 60 years
(b) No diagnosis of a CNS condition *	Including infections (e.g. meningitis), inflammatory diseases (e.g. multiple sclerosis), genetic conditions (e.g. Huntington's diseases), neurological conditions (e.g. autism), neurode-generative disorders (e.g. Parkinson's disease), or cancer.
(c) No diagnosis of a rheumatoid condition	E.g. lupus, rheumatoid arthritis, osteoarthritis.
(d) No acute pain at time of testing	E.g. temporary pain from mechanical trauma.
(e) No contradiction for receiving TES as dictated by equipment manufacturer.	E.g. unexplained fainting spells, familial history of epilepsy or diagnosis of epilepsy, heart conditions, shunts, stents, or implantable devices.
(f) No intake of gabapentinoids or prescribed analgesics in the month preceding testing.	Incidental intake of mild analgesics such as paracetamol or ibuprofen was allowed.
(g) No caffeine and alcohol 24hrs prior to testing.	-
<b>FM Patients</b>	
(a) A formal diagnosis of FM	Either by general practitioner or a rheumatologist.
(b) No other chronic pain condition	E.g. chronic nonspecific low back pain.

### **HC Participants**

(a) No diagnosis of any chronic pain condition	-
(b) Match an FM participant	By gender, age, ethnicity, site of stimulation and time of the day testing slot.

---

CNS – central nervous system, FM – fibromyalgia, HC – healthy control.

\* Apart from FM diagnosis for patients.


108 Participant characteristics pertinent to the study were gathered. These included  
109 demographic data (gender, age, ethnicity, marital status and years in education), medical  
110 history (any formal diagnoses) and medication intake (at present and preceding month).

### **111 2.2. Psychological Testing**

112 Presence or absence of FM was confirmed on the day of testing through the  
113 American College of Rheumatology Criteria from 1990, ACR '90, and 2010, ACR '10  
114 (Wolfe et al., 1990, 2010). The latter were scored considering the redactions from  
115 2016 (Wolfe et al., 2016). Recent pain history was assessed through the Short-Form  
116 McGill Pain Questionnaire, SF-MPQ (Melzack, 1987).

### **117 2.3. Psychophysical Testing**

118 All psychophysical testing was performed on the skin over the sural nerve at  
119 lateral border of tendo-Achilles. The testing setup can be seen in Figure 1. Body side  
120 was counterbalanced between participants. The area was to be free of skin damage,  
121 tattoos, and hair. Prior to placing electrodes, the stimulation site was cleaned with an  
122 abrasive gel followed by 70% isopropyl alcohol. Two disposable 2 cm self-adhesive  
123 disk electrodes were then positioned with inter-electrode distance of 3 cm.  
124 Impedance was checked by D175 impedance meter (Digimeter Ltd., United  
125 Kingdom) and was maintained below 50 kohm.



126

127 *Figure 1. Experimental Setup.* A. Equipment setup; B. Study stages; C. Acquired measures  
 128 at each study stage. VAS – visual analogue scale; TES – transcutaneous electrical  
 129 stimulator; ACR'90/10 – American College of Rheumatology Criteria for fibromyalgia  
 130 diagnosis from 1990 and 2010; SF-MPQ – Short-Form McGill Pain Questionnaire; STHR –  
 131 sensory threshold; PTHR – pain threshold; PTOL – pain tolerance; PRAN – pain range;  
 132 TS/A $\mu$  – average pain rating during temporal summation/adaptation; TS/Amax – maximal  
 133 pain rating during TS/A; A $\mu$  – minimal pain rating during A. Stimulator image is supplied by  
 134 manufacturer (Digitimer Ltd., UK) and sitting position image from Dimensions.Guide.  
 135 Reproduced from respective sources with permission.

136

137 **Stimulation Parameters.** Stimulation was delivered by a constant current  
 138 stimulator DS7AH Digitimer (Digitimer Ltd., UK). The equipment was operated semi-  
 139 automatically by the same experimenter: a computer maintained the frequency while  
 140 the experimenter adjusted the intensity. Stimulation was a single-square wave pulse  
 141 of 500  $\mu$ s duration, with maximum of 400V for the output.

142 **Psychophysical Measures.** To derive participant-specific stimulation levels,  
 143 static quantitative sensory testing (QST) was first performed. Three psychophysical  
 144 measures were collected: innocuous stimulus detection (ISD), pain threshold  
 145 (PTHR), and pain tolerance (PTOL). ISD was the first instance of any sensation at  
 146 the site of stimulation. PTHR was the first instance of stimulation being perceived as  
 147 painful. PTOL was the first instance of participant indicating that they no longer wish

148 to experience the next stimulation level increase. At each point, participants  
149 described the sensation to ensure understanding of instructions. Static QST was  
150 performed three times and each measure was defined as the average from these.

151 At the start of stimulation, the current was set at 0 mA and then increases in 0.1  
152 mA increments. Stimulation was delivered manually by experimenter at an  
153 approximate interval of 1 s to prevent adaptation. Maximal current intensity was  
154 predetermined to be 40 mA. If PTOL was not established prior to that, the stimulation  
155 was stopped. If more runs were left, the procedure was restarted. If during all runs  
156 the limit was reached, it was deemed that a participant's pain tolerance was not  
157 established, and they were excluded from further participation.

158 At the end of the procedure a secondary psychophysical measure was derived:  
159 pain range (PRAN), which was determined as the difference between pain threshold  
160 and tolerance ( $PTOL - PTHR = PR$ ).

## 161 **2.4. Continuous Pain Testing**

162 **Stimulation Conditions.** There were six stimulation levels 10%PRAN,  
163 20%PRAN, 30%PRAN, 40%PRAN, 50%PRAN, and 60%PRAN, calculated as  $PTHR$   
164  $+ (PRAN \times \% / 100)$ . Each stimulation intensity was delivered three times, resulting in  
165 18 experimental blocks, presented in a computer-randomised order. Short breaks  
166 (no more than 1 min) were available between each block, with mandatory longer  
167 breaks after the 6<sup>th</sup> and 12<sup>th</sup> blocks (no more than 5 min).

168 **Stimulation Parameters.** During continuous pain testing, stimulation protocol  
169 was adjusted to elicit TS. The current remained as single-wave pulses with 500  $\mu$ s  
170 duration and up to 50 V. Instead of manual stimuli delivery, a computer maintained a  
171 2.5 Hz frequency. Current intensity was dictated by stimulation condition and was  
172 thus always within acceptable to the participant range. The experimenter was  
173 responsible for the manual adjustment of intensity and did so before each block,  
174 without the awareness of the participant.

175 **Continuous Pain Rating.** To continuously reassess pain, a pain visual  
176 analogue scale (VAS) was used. The scale ranged from '0' to '100', with major ticks  
177 at every tenth mark. On the scale '0' was no pain, '1' was minimal pain, and '100'  
178 was the worst pain imaginable. Participants were instructed to constantly rate the

179 experienced pain for the duration of the stimulation block. If other pain was present,  
180 which was the case for the clinical cohort, participants were to exclude it from the  
181 rating.

182 The rating was provided using a proprietary response device fitted with an  
183 Arduino Genuino (Arduino LLC) and a rotary button. By adjusting the rotation of the  
184 button, participants adjusted a sliding marker on the VAS. It is the position of that  
185 marker that was constantly resampled every 200 ms.

## 186 **2.5. Analysis**

187 Analysis was carried out in RStudio (v. 1.0.136).

188 Participant characteristics were summarised through average values and  
189 standard deviation (*SD*). Group differences were assessed through separate  
190 Student's t-tests (two-tailed, with post-hoc Bonferroni correction) where appropriate.

191 **Psychological Testing.** Cumulative and subsection questionnaire scores were  
192 summarised as average values and *SD*. Student's t-test (two-tailed) was used to  
193 compare cohorts on all forms.

194 **Psychophysical Testing.** *STHR*, *PTHR* and *PTOL* were calculated as the  
195 mean of each of the three recorded measurements. The average of each values was  
196 compared between groups through a Student's t-test (two-tailed, with post-hoc  
197 Bonferroni correction). Group level mean, *SD*, and range were used to describe  
198 psychophysical values. The same procedure was repeated for stimulation conditions.

199 **Continuous Pain Testing.** To assess whether the presence of FM diagnosis  
200 was related to increased average and continuous pain ratings, key events and  
201 timepoints were extracted from the data for analysis. Figure 1, panel A) shows a  
202 prototypical pain response with measures of interest. First the response was broken  
203 into period of *TS* (0 to 15 s) and period of adaptation (15 s to 60 s). An average pain  
204 rating was calculated for each period (***TS $\mu$***  and ***A $\mu$*** ) to assess the overall pain rating  
205 for that period. Then maximal pain ratings were then extracted for each period  
206 (***TS $\mu$ max*** and ***A $\mu$ max***). Both value and time were recorded for each, resulting in the  
207 variables ***TS $\mu$ max-v***, ***TS $\mu$ max-t***, ***A $\mu$ max-v***, ***A $\mu$ max-t***. Lastly, for the *TS* period we  
208 calculated the slope from start of response to ***TS $\mu$ max*** (***TS $\mu$ m***) to quantify the time  
209 needed to reach maximal rating during *TS*.

210 To analyse what factors predict the measures we used mixed-effect modelling.  
211 Separate models were created for each of the seven outcome variables. Predictors'  
212 inclusion was predetermined based on relevancy to hypotheses. *Group* (FM vs HC)  
213 was entered as a fixed factor to determine whether the presence of a diagnosis is  
214 associated with an increase in pain measures. *Stimulation* (stimulation intensity in  
215 mA) was entered as a fixed factor to account for the mediating effects of stimulation  
216 intensity. And finally, *Participant* was entered as a random effect, to account for  
217 individual variance.

218 Model syntax was guided by protocol described elsewhere (Brysbaert &  
219 Stevens, 2018; Matuschek et al., 2017), suitable for minimising Type I error in small  
220 samples. Sample size was estimated through power simulations following an  
221 established method (Green & MacLeoud, 2016). A Kenward-Roger approximation  
222 was calculated for each fixed covariate, with the goal of observing  $\geq 80\%$  power for  
223 effect size .5.

224

## 225 **RESULTS**

226 33 participants met all eligibility requirements. Three participants from the  
227 control cohort were unable to complete the experiment due to failure to establish  
228 PTOL, thus leaving a sample of 30 participants. 17 were FM participants and 13  
229 were pain-free controls.

### 230 **3.1. Participants & Psychological Testing**

231 All participants were Caucasian females. No significant differences were found  
232 between samples on individual characteristics (see Table 2). Psychological testing  
233 did find that the FM sample experienced more pain due to their condition in the week  
234 preceding testing.

235

236

237

238

239 **Table 2. Descriptive Statistics for Participants Samples & Psychological Testing**

	<i>Mean (SD)</i>		<i>p-value</i>
	<i>FM</i>	<i>HC</i>	
Age (n years)	35.35 (11.9)	35.7 (12.84)	.941
Education (n years)	17.88 (2.23)	18.46 (2.3)	.492
Marital Status (n married) <sup>a</sup>	9 (53%)	4 (31%)	-
FM diagnosis duration (years)	3.63 (3.13)	-	-
FM symptoms duration (years)	10.04 (7.98)	-	-
Medication in the last 30 day <sup>*</sup>	17 (100%)	4 (31%)	-
Analgesics <sup>a b</sup>	12 (71%)	3 (18%)	-
Anticonvulsants <sup>a</sup>	1 (6%)	-	-
Antidepressants <sup>a</sup>	10 (59%)	1 (8%)	-
<b>ACR'90</b>			
Widespread Pain	7.76 (.75)	.15 (.38)	< .001 ***
Tender Points	14.24 (2.49)	.31 (.63)	< .001 ***
<b>ACR'10</b>			
Widespread Pain Index	13.88 (3.18)	1.54 (1.44)	< .001 ***
Somatic Symptoms Severity	7.65 (1.58)	1.92 (2.22)	< .001 ***
Other Somatic Symptoms	2.06 (.56)	1.08 (.64)	< .001 ***
<b>SF-MPQ</b>			
Pain Descriptors	24.77 (7.4)	2.85 (2.61)	< .001 ***
Visual Analog Scale	6.65 (1.37)	1.15 (.8)	< .001 ***
Present Pain Intensity	3 (1.23)	-	-

240 SD – standard deviation, FM – fibromyalgia group, HC – healthy control group. P-values  
 241 were calculated using Student's t-test. Post-hoc Bonferroni correction indicated corrected p-  
 242 value of < .006.

243 <sup>a</sup> Number and percentage calculated.

244 <sup>b</sup> Analgesics included mild over the counter medication.

245 \*\*\* Statistically significant.

### 246 **3.2. Psychophysical Testing**

247 No significant group differences were observed for STHR and PTHR (see Table  
 248 3). Both PTOL and PRAN were significantly higher in the clinical sample, just as all  
 249 stimulation levels.

250 **Table 3. Average Values (mA) for Psychophysical Measures & Stimulation Levels**

	<i>FM</i>		<i>HC</i>		<i>p-value</i>
	<i>Mean (SD)</i>	<i>Range</i>	<i>Mean (SD)</i>	<i>Range</i>	
STHR	1.38 (0.49)	.73 – 2.3	1.5 (0.33)	1 – 1.97	.427
PTHR	4.71 (2.83)	1.97 – 13.17	6.57 (3.62)	2.43 – 13.9	.124
PTOL	11.82 (7.85)	5.3 – 34.33	22.14 (9.75)	9.33 – 38.9	.003 ***
PRAN	7.11 (5.7)	2.53 – 24.5	15.57 (8.22)	5.6 – 27.5	.002 ***
10% PRAN	5.42 (3.23)	2.3 – 14.69	8.13 (3.89)	3.12 – 16.37	.047
20% PRAN	6.13 (3.67)	2.7 – 16.22	9.68 (4.32)	3.81 – 18.87	.022
30% PRAN	6.84 (4.15)	3 – 17.75	11.24 (4.84)	4.5 – 21.37	.012
40% PRAN	7.55 (4.65)	3.3 – 19.63	12.8 (5.44)	5.19 – 23.87	.008
50% PRAN	8.27 (5.16)	3.7 – 22.08	14.35 (6.09)	5.88 – 26.37	.006
60%PRAN	8.98 (5.69)	4 – 24.53	15.91 (6.78)	6.57 – 28.87	.005 ***

251 SD – standard deviation, FM – fibromyalgia group, HC – healthy controls group, STHR –  
 252 sensory threshold, PTHR – pain threshold, PTOL – pain tolerance, PRAN – pain range. P-  
 253 values were calculated using Student’s t-test. Post-hoc Bonferroni correction indicated  
 254 corrected p-value of < .005.

255 \*\*\* Statistically significant.

256

### 257 **3.3. Continuous Pain Testing**

258 The best mixed-fixed effects model for all measures had the following formula:

259 
$$\sim \text{Group} + \text{Stimulation} + (1 + \text{Stimulation} | \text{Participant})$$

260 A full model summary can be found in Supplementary Material 1. Analysis of  
 261 **TS $\mu$**  showed that it is significantly associated with Stimulation (*Coeff.* = 5.56, *SE* =  
 262 6.52, *t* = 7.14, *p* < .001) but not Group (*Coeff.* = 10.64, *SE* = 6.52, *t* = 1.63, *p* = .110),  
 263 indicating that an increase in stimulus intensity was reflected in the average rating for  
 264 the period, unlike the presence of diagnosis. Marginal means estimated based on  
 265 that model show a trend for increased pain rating in FM group (see Table 4). This  
 266 trend, however, was not statistically significant, a pattern that was repeated in the  
 267 subsequent analyses of TS pain measures.

268 *Table 4. Estimated Marginal Means.*

Group	EMM	SE	95% CI	
			Lower	Upper
<b>TS <math>\mu</math></b>				
HC	24.12	(6.49)	11.03	37.22
FM	34.76	(5.86)	22.94	46.59
<b>TSmax.v</b>				
HC	36.47	(9.61)	17.09	55.86
FM	50.51	(8.69)	32.98	68.03
<b>TSmax.t *</b>				
HC	7.38	(.98)	5.39	9.37
FM	10.56	(.91)	8.72	12.39
<b>TSm</b>				
HC	6.36	(.79)	4.74	7.97
FM	6.76	(.71)	5.32	8.2
<b>A<math>\mu</math></b>				
HC	30.48	(9.61)	11.05	49.91
FM	50.52	(8.6)	33.15	67.88
<b>Amax.v *</b>				
HC	29.25	(9.3)	10.39	48.12
FM	59.05	(8.32)	42.22	75.88
<b>Amax.t *</b>				
HC	24.33	(3.31)	17.58	31.07
FM	36.81	(3.05)	30.66	42.97

269 EMM – estimated marginal means, SE – standard error, CI – confidence interval.

270 \* Significant ( $p < .05$ ) group difference established in respective linear mixed-effects models.

271

272 The magnitude of the maximal TS pain rating (**TSmax.v**) was similarly  
 273 predicted by Stimulation (*Coeff.* = 7.81, *SE* = 1.08,  $t = 7.22$ ,  $p < .001$ ) but not the  
 274 Group (*Coeff.* = 14.03, *SE* = 9.53,  $t = 1.47$ ,  $p = .152$ ). The time when the maximal  
 275 rating was made (**TSmax.t**), however, was significantly associated both with  
 276 Stimulation (*Coeff.* = .51, *SE* = .09,  $t = 5.46$ ,  $p < .001$ ) and Group (*Coeff.* = 3.17, *SE*

277 = 1.23,  $t = 2.58$ ,  $p = .016$ ). Increase in stimulation slightly increased the time to the  
278 peak rating. Separately, belonging to the FM cohort was associated with an  
279 additional almost 3 s delay (see Table 4).

280 The slope from the start of the response to the maximal pain rating (**TS<sub>m</sub>**) was  
281 not related to Stimulation ( $Coeff. = .14$ ,  $SE = .08$ ,  $t = 1.8$ ,  $p = .089$ ) or Group ( $Coeff. =$   
282  $.41$ ,  $SE = .98$ ,  $t = .42$ ,  $p = .681$ ), suggesting that the slope did not differ on basis of  
283 stimulus intensity nor the presence of FM diagnosis.

284 The average pain rating during the period of adaptation (**A<sub>μ</sub>**) significantly  
285 increased with Stimulation ( $Coeff. = 8.15$ ,  $SE = .98$ ,  $t = 8.29$ ,  $p < .001$ ) but not Group  
286 ( $Coeff. = 20.04$ ,  $SE = 10.6$ ,  $t = 1.89$ ,  $p = .069$ ). As with **TS<sub>μ</sub>**, the trend exhibited by  
287 FM patients for higher average pain rating for the period did not reach statistical  
288 significance.

289 In contrast, the maximal rating made during adaptation (**A<sub>max.v</sub>**) was sensitive  
290 to both stimulation and presence of diagnosis. An increase of Stimulation intensity  
291 was associated with an increase of reported pain ( $Coeff. = 7.96$ ,  $SE = .97$ ,  $t = 8.23$ ,  $p$   
292  $< .001$ ). The FM Group additionally produced significantly higher maximal pain  
293 ratings during adaptation ( $Coeff. = 29.8$ ,  $SE = 10.87$ ,  $t = 2.74$ ,  $p = .011$ ). The same  
294 was true for the time the peak rating was made (**A<sub>max.t</sub>**). Increased Stimulation  
295 ( $Coeff. = 1.26$ ,  $SE = .37$ ,  $t = 3.41$ ,  $p = .006$ ) and belonging to the FM group ( $Coeff. =$   
296  $12.49$ ,  $SE = 4.1$ ,  $t = 3.04$ ,  $p = .005$ ) predicted a delay in reaching that maximal rating.

297

## 298 **DISCUSSION**

299 Despite a large body of research reporting augmented TS in FM (O'Brien et al.,  
300 2018), several studies have failed to consistently achieve the same results (Lim et  
301 al., 2016; Potvin et al., 2012; Staud et al., 2008). To address this discrepancy, we  
302 adopted a different pain measurement approach, in which pain perception was  
303 assessed through continuously gathered pain ratings. Using it, we were able to  
304 analyse not only the value of a given pain rating but also the time it was made.

305 We found that FM was significantly associated with delays in reaching peak  
306 pain ratings during the periods of TS and adaptation. In contrast, only the magnitude  
307 of the maximal peak rating during adaptation differed significantly between cohorts.


308 The value of the peak TS rating was not significantly associated with diagnosis, and  
309 neither was the slope to that peak. Average pain rating during TS and adaptation  
310 were also not found to be significantly different between participant groups. The best  
311 mixed-effects model for each measure included stimulation intensity as a factor.  
312 Apart from the TS slope, all measures were found to be predicted by it. An increase  
313 in stimulus intensity was mirrored by an increase in average pain ratings during TS  
314 and adaptation, as well as magnitude and time of maximal ratings. Together, the  
315 findings show that continuous pain report not only enabled the extraction of a new  
316 variable property but that it was this temporal property that was consistently  
317 associated with the presence of FM diagnosis.

318 Although using the maximal pain rating in response to TS eliciting stimulation  
319 has been the conventional approach to characterising central sensitisation in FM  
320 (Staud et al., 2001), our study suggests that this may be only one of several markers  
321 of deficient pain modulation. In previous studies, pain ratings were collected at  
322 predetermined timepoints following a prolonged stimulation needed to elicit TS  
323 (Staud et al., 2001). This both limited the measurement window and the number of  
324 observations. In our study, we purposefully extended the pain rating collection time.  
325 This gave us sufficient time to measure the TS part of the response, as well as to  
326 observe how participants adapt to pain post-TS. Let us consider both in succession.  
327 First, the extended record enabled the flexible extraction of maximal TS rating. We  
328 propose that it was this key change that allowed us to observe significant group  
329 differences in the TS period. It may be that previous research, which was not  
330 successful in finding augmented TS, measured peak TS rating too early, as our  
331 results indicate that FM patients were slow in reaching their peak rating. That delay  
332 is of particular importance when considered together with analysis of the later  
333 adaptation period.

334 Extending data collection past the TS period was the second major  
335 advancement of our study. The conventional focus on TS as a method of quantifying  
336 centrally dysregulated pain modulation in FM had demotivated further inspection into  
337 *how* participants adapt to prolonged pain. This is different to studies where  
338 aftersensations to TS-inducing pain stimulation were studied (Banic et al., 2004).  
339 Here, we were interested to observe whether FM participants continue to rate their  
340 pain increasingly high, thus indicating sensitisation, or whether they would slowly

341 begin to habituate to it, evident in reduced pain ratings. The finding that maximal  
342 adaptation rating was not only higher but reached later by the FM group suggests  
343 that these participants continued to sensitise to the stimulation. The yet again  
344 delayed peak further supports the idea of disrupted pain inhibition under FM (Sluka &  
345 Clauw, 2016).

346 Our study also agreed with previous research that hyperalgesia is integral to the FM  
347 pain profile (Nielsen & Henriksson, 2007). We chose to apply individually-derived  
348 stimulation conditions in order to demonstrate the differences in sensitivity between  
349 the participant cohorts. Despite the stimulation levels being calculated so that  
350 comparable pain ratings are be observed between participants, this was not found.  
351 For example, the 10% PRAN condition should have elicited pain ratings around the  
352 10th mark on the VAS, regardless of which group the participant belonged to. As  
353 could be seen in Figure 3, however, patients consistently provided ratings higher  
354 than their pain-free counterparts. Further, the average stimulation values were lower  
355 in the FM group, yet they still rated the evoked pain as higher than the control.  
356 Together, this pattern of results suggests that hyperalgesia, a key marker of central  
357 sensitisation, is present in FM.



358

359 **Figure 3. Average Trajectory of Continuous Pain Ratings per Stimulation Condition.**

360 VAS – visual analogue scale, PRAN – pain range; HC – healthy control; FM – fibromyalgia.

361

362 It is interesting that HC participants produced consistently lower ratings than  
363 those expected for the respective stimulation condition. Perhaps the trend is partially  
364 attributable to habituation. The ability to adjust to continuous mild nociceptive input is  
365 part of the CNS regulatory mechanisms. The failure to see a similar effect in FM  
366 participants further supports the theory of the CNS origin of the syndrome (Nielsen &  
367 Henriksson, 2007).

### 368 **Limitations & Future Directions**

369 Unlike other studies (Staud et al., 2005), we only examined continuous pain  
370 report in response to TES. Research has shown that a comprehensive pain profile  
371 can only be achieved when testing pain perception through multiple stimulus  
372 modalities (Hastie et al., 2005). In FM, employing a multidimensional pain testing  
373 protocol with continuous pain ratings would further clarify the role of time in the  
374 augmented development of TS and adaptation. Further, the focus of the current  
375 study were only behavioural markers of central sensitisation. It remains unclear how  
376 does the subjective pain report connect to the physiological response. Although, TS  
377 and adaptation are assumed to reflect underlying WU (Graven-Nielsen et al., 2000),  
378 psychological modulators such as stress have been theorised to mediate self-  
379 reported pain at supraspinal level (Crettaz et al., 2013). A concurrent measurement  
380 of both TS and WU is not only plausible due the common stimulation protocol but  
381 would also be useful in the clarification of their relationship and allow for further  
382 investigation of psychological mediating factors. Lastly, while the benefits of  
383 individually derived stimulation levels were evident, they do complicate data  
384 interpretation. Here we calculated stimulation conditions using an individual's pain  
385 range, which led us to deliver vastly different stimulation between cohorts. The  
386 alternative approach where predetermined values are used may be adopted instead.

### 387 **Conclusion**

388 Continuous pain ratings of TES were simple to implement while rich in  
389 produced data. The newly extracted time property of the maximal pain ratings made  
390 during TS and adaptation were found to be reliable measures of differentiation  
391 between FM-diagnosed and pain-free cohorts. Analysis of the later pain response

392 period, adaptation, was also beneficial for the characterisation of central sensitisation  
393 in FM, and should be analysed alongside of TS in future investigations.

394

395 **Acknowledgments**

396           The authors thank Carol Hambly, the organiser of a local Fibromyalgia Support  
397 Group for her support in participant recruitment.

398

399 **Disclosures**

400           Anna Kharko received funding from the School of Psychology, University of  
401 Plymouth, to carry out the study. The grant provider had no input into the conduct of  
402 the study. The other authors have no conflicts of interest to declare.

## 403 References

- 404 Arendt-Nielsen, L., Sonnenborg, F. A., & Andersen, O. K. (2000). Facilitation of the  
405 withdrawal reflex by repeated transcutaneous electrical stimulation: An  
406 experimental study on central integration in humans. *European Journal of*  
407 *Applied Physiology*, 81(3), 165–173. <https://doi.org/10.1007/s004210050026>
- 408 Banic, B., Petersen-Felix, S., Andersen, O. K., Radanov, B. P., Villiger, M. P.,  
409 Arendt-Nielsen, L., & Curatolo, M. (2004). Evidence for spinal cord  
410 hypersensitivity in chronic pain after whiplash injury and in fibromyalgia: *Pain*,  
411 107(1), 7–15. <https://doi.org/10.1016/j.pain.2003.05.001>
- 412 Boormans, E. M., van Kesteren, P. J., Perez, R. S., Brölmann, H. A., & Zuurmond,  
413 W. W. (2009). Reliability of a Continuous Pain Score Meter: Real Time Pain  
414 Measurement. *Pain Practice*, 9(2), 100–104. <https://doi.org/10.1111/j.1533-2500.2009.00260.x>
- 416 Brysbaert, M., & Stevens, M. (2018). Power Analysis and Effect Size in Mixed  
417 Effects Models: A Tutorial. *Journal of Cognition*, 1(1), 9.  
418 <https://doi.org/10.5334/joc.10>
- 419 Clauw, D. J. (2014). Fibromyalgia: A Clinical Review. *JAMA*, 311(15), 1547–1555.  
420 <https://doi.org/10.1001/jama.2014.3266>
- 421 Crettaz, B., Marziniak, M., Willeke, P., Young, P., Hellhammer, D., Stumpf, A., &  
422 Burgmer, M. (2013). Stress-Induced Allodynia – Evidence of Increased Pain  
423 Sensitivity in Healthy Humans and Patients with Chronic Pain after  
424 Experimentally Induced Psychosocial Stress. *PLOS ONE*, 8(8), e69460.  
425 <https://doi.org/10.1371/journal.pone.0069460>
- 426 Gebhart, G. F., & Schmidt, R. F. (Eds.). (2013). Wind-Up (Phenomenon). In  
427 *Encyclopedia of Pain* (pp. 4267–4267). Springer. [https://doi.org/10.1007/978-3-642-28753-4\\_202471](https://doi.org/10.1007/978-3-642-28753-4_202471)
- 429 Graven-Nielsen, T., Kendall, S. A., Henriksson, K. G., Bengtsson, M., Soërensen, J.,  
430 Johnson, A., Gerdle, B., & Arendt-Nielsen, L. (2000). Ketamine reduces  
431 muscle pain, temporal summation, and referred pain in fibromyalgia patients.  
432 *Pain*, 9.
- 433 Hastie, B. A., Riley, J. L., Robinson, M. E., Glover, T., Campbell, C. M., Staud, R., &  
434 Fillingim, R. B. (2005). Cluster analysis of multiple experimental pain  
435 modalities. *Pain*, 116(3), 227–237. <https://doi.org/10.1016/j.pain.2005.04.016>
- 436 Häuser, W., Walitt, B., Fitzcharles, M.-A., & Sommer, C. (2014). Review of  
437 pharmacological therapies in fibromyalgia syndrome. *Arthritis Research &*  
438 *Therapy*, 16(1), 201. <https://doi.org/10.1186/ar4441>
- 439 Lim, M., Roosink, M., Kim, J. S., Kim, H. W., Lee, E. B., Son, K. M., Kim, H. A., &  
440 Chung, C. K. (2016). Augmented Pain Processing in Primary and Secondary  
441 Somatosensory Cortex in Fibromyalgia: A Magnetoencephalography Study  
442 Using Intra-Epidermal Electrical Stimulation. *PLOS ONE*, 11(3), e0151776.  
443 <https://doi.org/10.1371/journal.pone.0151776>

- 444 Matuschek, H., Kliegl, R., Vasishth, S., Baayen, H., & Bates, D. (2017). Balancing  
445 Type I error and power in linear mixed models. *Journal of Memory and*  
446 *Language*, 94, 305–315. <https://doi.org/10.1016/j.jml.2017.01.001>
- 447 Meeus, M., & Nijs, J. (2007). Central sensitization: A biopsychosocial explanation for  
448 chronic widespread pain in patients with fibromyalgia and chronic fatigue  
449 syndrome. *Clinical Rheumatology*, 26(4), 465–473.  
450 <https://doi.org/10.1007/s10067-006-0433-9>
- 451 Melzack, R. (1987). The short-form McGill Pain Questionnaire. *Pain*, 30(2), 191–197.  
452 [https://doi.org/10.1016/0304-3959\(87\)91074-8](https://doi.org/10.1016/0304-3959(87)91074-8)
- 453 Nielsen, L. A., & Henriksson, K. G. (2007). Pathophysiological mechanisms in  
454 chronic musculoskeletal pain (fibromyalgia): The role of central and peripheral  
455 sensitization and pain disinhibition. *Best Practice & Research Clinical*  
456 *Rheumatology*, 21(3), 465–480. <https://doi.org/10.1016/j.berh.2007.03.007>
- 457 O'Brien, A. T., Deitos, A., Triñanes Pego, Y., Fregni, F., & Carrillo-de-la-Peña, M. T.  
458 (2018). Defective Endogenous Pain Modulation in Fibromyalgia: A Meta-  
459 Analysis of Temporal Summation and Conditioned Pain Modulation  
460 Paradigms. *The Journal of Pain*, 19(8), 819–836.  
461 <https://doi.org/10.1016/j.jpain.2018.01.010>
- 462 Potvin, S., Paul-Savoie, E., Morin, M., Bourgault, P., & Marchand, S. (2012).  
463 Temporal Summation of Pain Is Not Amplified in a Large Proportion of  
464 Fibromyalgia Patients. *Pain Research and Treatment*, 2012, 1–6.  
465 <https://doi.org/10.1155/2012/938595>
- 466 Queiroz, L. P. (2013). Worldwide Epidemiology of Fibromyalgia. *Current Pain and*  
467 *Headache Reports*, 17(8), 356. <https://doi.org/10.1007/s11916-013-0356-5>
- 468 Sluka, K. A., & Clauw, D. J. (2016). Neurobiology of fibromyalgia and chronic  
469 widespread pain. *Neuroscience*, 338, 114–129.  
470 <https://doi.org/10.1016/j.neuroscience.2016.06.006>
- 471 Staud, R. (2012). Abnormal endogenous pain modulation is a shared characteristic  
472 of many chronic pain conditions. *Expert Review of Neurotherapeutics*, 12(5),  
473 577–585. <https://doi.org/10.1586/ern.12.41>
- 474 Staud, R., Cannon, R. C., Mauderli, A. P., Robinson, M. E., Price, D. D., & Jr, C. J.  
475 V. (2003). *Temporal summation of pain from mechanical stimulation of muscle*  
476 *tissue in normal controls and subjects with fibromyalgia syndrome*. 10.
- 477 Staud, R., Craggs, J. G., Perlstein, W. M., Robinson, M. E., & Price, D. D. (2008).  
478 Brain activity associated with slow temporal summation of C-fiber evoked pain  
479 in fibromyalgia patients and healthy controls. *European Journal of Pain*, 12(8),  
480 1078–1089. <https://doi.org/10.1016/j.ejpain.2008.02.002>
- 481 Staud, R., Price, D. D., Robinson, M. E., Mauderli, A. P., & Vierck, C. J. (2004).  
482 Maintenance of windup of second pain requires less frequent stimulation in  
483 fibromyalgia patients compared to normal controls: *Pain*, 110(3), 689–696.  
484 <https://doi.org/10.1016/j.pain.2004.05.009>

- 485 Staud, R., Vierck, C. J., Cannon, R. L., Mauderli, A. P., & Price, D. D. (2001).  
486 Abnormal sensitization and temporal summation of second pain (wind-up) in  
487 patients with fibromyalgia syndrome: *Pain*, 91(1), 165–175.  
488 [https://doi.org/10.1016/S0304-3959\(00\)00432-2](https://doi.org/10.1016/S0304-3959(00)00432-2)
- 489 Staud, R., Vierck, C. J., Robinson, M. E., & Price, D. D. (2005). Effects of the N-  
490 methyl-D-aspartate receptor antagonist dextromethorphan on temporal  
491 summation of pain are similar in fibromyalgia patients and normal control  
492 subjects. *The Journal of Pain: Official Journal of the American Pain Society*,  
493 6(5), 323–332. <https://doi.org/10.1016/j.jpain.2005.01.357>
- 494 Staud, R., Weyl, E. E., Riley, J. L., & Fillingim, R. B. (2014). Slow Temporal  
495 Summation of Pain for Assessment of Central Pain Sensitivity and Clinical  
496 Pain of Fibromyalgia Patients. *PLoS ONE*, 9(2), e89086.  
497 <https://doi.org/10.1371/journal.pone.0089086>
- 498 Wijk, A. J. van, Lobbezoo, F., & Hoogstraten, J. (2013). Reliability and validity of a  
499 continuous pain registration procedure. *European Journal of Pain*, 17(3), 394–  
500 401. <https://doi.org/10.1002/j.1532-2149.2012.00194.x>
- 501 Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., Goldenberg, D. L., Häuser, W., Katz, R.  
502 L., Mease, P. J., Russell, A. S., Russell, I. J., & Walitt, B. (2016). 2016  
503 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. *Seminars in*  
504 *Arthritis and Rheumatism*, 46(3), 319–329.  
505 <https://doi.org/10.1016/j.semarthrit.2016.08.012>
- 506 Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., Goldenberg, D. L., Katz, R. S., Mease, P.,  
507 Russell, A. S., Russell, I. J., Winfield, J. B., & Yunus, M. B. (2010). The  
508 American College of Rheumatology Preliminary Diagnostic Criteria for  
509 Fibromyalgia and Measurement of Symptom Severity. *Arthritis Care &*  
510 *Research*, 62(5), 600–610. <https://doi.org/10.1002/acr.20140>
- 511 Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg,  
512 D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., Fam, A. G., Farber,  
513 S. J., Fiechtner, J. J., Franklin, C. M., Gatter, R. A., Hamaty, D., Lessard, J.,  
514 Lichtbroun, A. S., Masi, A. T., ... Sheon, R. P. (1990). The american college of  
515 rheumatology 1990 criteria for the classification of fibromyalgia. *Arthritis &*  
516 *Rheumatism*, 33(2), 160–172. <https://doi.org/10.1002/art.1780330203>
- 517